Euglycemic diabetic ketoacidosis induced by dapagliflozin

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-HPS-036
• By: LIN, Chia-Fang (Chang Gung Memorial Hosipital, Taoyuan, Taiwan, Department of Pharmacy, Taoyuan, China Taiwan)
• Co-author(s): Chia-Fang Lin: Department of Pharmacy, Chang Gung Memorial Hosipital, Taoyuan, Taiwan, Taoyuan, Taiwan, Province of China
  Hsuan-Ling Hsiao: Department of Pharmacy, Chang Gung Memorial Hosipital, Taoyuan, Taiwan, Taoyuan, Taiwan, Province of China
  Tzu-Cheng Tsai: Department of Pharmacy, Chang Gung Memorial Hosipital, Taoyuan, Taiwan, Taoyuan, Taiwan, Province of China
  Shin-Tarng Deng: Department of Pharmacy, Chang Gung Memorial Hosipital, Taoyuan, Taiwan, Taoyuan, Taiwan, Province of China
  
• Abstract:

  Background

  Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the newest class of oral antihyperglycemic medications to be approved for the treatment of patients with type 2 diabetes mellitus as one of second-line therapy options. Recent evidence warns of an increased risk of diabetic ketoacidosis (DKA) with nonspecifically mild to moderate..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login